RGLS - レグルス・セラピュ―ティクス （Regulus Therapeutics Inc.） レグルス・セラピュ―ティクスRGLSのチャート
RGLSの企業情報
| symbol | RGLS |
|---|---|
| 会社名 | Regulus Therapeutics Inc （レグルス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 レグルス・セラピューティクス(Regulus Therapeutics Inc.)はミクロリボ核酸（RNA）をターゲットとして種々の疾患を治療するためのファーストインクラスの薬剤の発見と開発を中心とするバイオ医薬品会社。ミクロRNAは自然発生的なリボ核酸で、重要な生物学的経路の調節に大切な役割を果たす分子である。同社はミクロRNA製品ラットフォームを使用してアンチmiRと呼ばれる、化学的に修飾された一本鎖オリゴヌクレオチドを開発する。同社はこれらアンチmiRを使用してミクロRNAを調節して、異常細胞を健康状態に返す。平成24年8月、同社は心血管疾患、代謝性疾患と腫瘍のためのミクロRNA治療薬を発見・開発するために、AstraZenecaと戦略的提携を形成した。 レグルス・セラピュ―ティクスは米国のバイオ製薬会社。マイクロRNAを標的とする医薬品の探索と開発に従事。製品は、C型肝炎感染症、心臓血管疾患、線維症、がん、メタボリックなどの治療に用いる。アストラゼネカ、グラクソスミスクライン、サノフィ、バイオジェン・アイデックなどとの戦略的提携を進める。本社はカリフォルニア州サンディエゴ。 Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in La Jolla, CA. |
| 本社所在地 | 10614 Science Center Drive San Diego CA 92121 USA |
| 代表者氏名 | Stelios Papadopoulos Stelios Papadopoulos |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-202-6300 |
| 設立年月日 | 39326 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2012年 |
| 従業員数 | － |
| url | www.regulusrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rgls |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -55.76000 |
| 終値（lastsale） | 2.36 |
| 時価総額（marketcap） | 20618213.16 |
| 時価総額 | 時価総額（百万ドル） 16.16258 |
| 売上高 | 売上高（百万ドル） 0.07200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3.19458 |
| 当期純利益 | 当期純利益（百万ドル） -23.89900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Regulus Therapeutics Inc revenues remained flat at $36K. Net loss decreased 28% to $29.9M. Revenues reflect market conditions. Lower net loss reflects research decrease of 28% to $20.4M (expense) general decrease of 37% to $5.6M (expense) Stock-based Compensation in SGA decrease of 30% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$9.41 to -$3.44. |
RGLSのテクニカル分析
RGLSのニュース
Hot Stock’s Alert: Regulus Therapeutics Inc. (NASDAQ:RGLS 1.90%), Akari Therapeutics, Plc (NASDAQ:AKTX 4.62%) 2023/02/04 13:37:20 Stock Equity
Regulus Therapeutics Inc. (NASDAQ:RGLS) with the stream of 1.90% also noticed, India Akari Therapeutics, Plc (NASDAQ:AKTX) encountered a rapid change of 4.62% in the last hour of Friday’s trading session. … The post Hot Stock’s Alert: Regulus Therapeutics Inc. (NASDAQ:RGLS 1.90%), Akari Therapeutics, Plc (NASDAQ:AKTX 4.62%) appeared first on Stocks Equity .
Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Forecast: Bearish Sentiment Points To -504.03% Downside In 2023 2023/01/16 18:00:00 Stocks Register
The trading price of Regulus Therapeutics Inc. (NASDAQ:RGLS) closed lower on Friday, January 13, closing at $1.49, -5.70% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.49 and $1.59. In examining the 52-week price action we see that the stock hit a 52-week … Regulus Therapeutics Inc. (NASDAQ: RGLS) Stock Forecast: Bearish Sentiment Points To -504.03% Downside In 2023 Read More »
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript 2022/11/11 02:49:13 Seeking Alpha
Regulus Therapeutics, Inc. (NASDAQ:NASDAQ:RGLS) Q3 2022 Earnings Conference Call November 10, 2022, 17:00 ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO &…
Regulus Therapeutics GAAP EPS of -$0.50 (NASDAQ:RGLS) 2022/11/10 21:20:39 Seeking Alpha
Regulus Therapeutics press release (RGLS): Q3 GAAP EPS of -$0.50.Cash, Cash Equivalents and Marketable Securities: As of September 30, 2022, Regulus had $45.3 million in cash,…
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates 2022/11/10 21:05:00 PR Newswire
Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Company announced positive topline safety and pharmacokinetic (PK) data from its Phase 1 Single-Ascending Dose (SAD)…
After A Decline Of -428.57% From The High, Can Regulus Therapeutics Inc. (NASDAQ: RGLS) Recover Quickly? 2022/05/27 15:00:00 Marketing Sentinel
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s traded shares stood at 1.64 million during the last session, with the company’s beta value hitting 2.09. At the close of trading, the stock’s price was $0.28, to imply an increase of 13.19% or $0.04 in intraday trading. The RGLS share’s 52-week high remains $1.48, putting it -428.57% down since that … After A Decline Of -428.57% From The High, Can Regulus Therapeutics Inc. (NASDAQ: RGLS) Recover Quickly? Read More »
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference 2022/05/17 20:30:00 PR Newswire
SAN DIEGO, May 17, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive…
7 Penny Stocks With 10x Potential This Year 2022/05/17 11:00:28 InvestorPlace
Penny stocks can multiply in value quickly, these picks have 10x potential this year. Regulus Therapeutics ( RGLS ): Represents traditional pharma potential and proven returns for traders. Imperial Petroleum ( IMPP ): Traders have shown their appreciation for Imperial Petroleum which has already gone 10X this year. Kintara Therapeutics ( KTRA ): A pharma firm that’s on the edge but analysts believe it has 20X potential built in. ObsEva ( OBSV ): Female reproductive health biotech with a significant catalyst in September. Mullen Automotive ( MULN ): Lots of upside despite a swirl of negativity. Fiore Cannabis ( FIORF ): Canadian medical and recreational cannabis firm with 10X potential baked into prices. Foresight Autonomous Holdings ( FRSX ): Israeli vision firm focused on vehicular accident prevention. Source: Shutterstock It’s no secret that the stock market has faced severe turbulence in 2022 that will likely continue. That implies that an appetite for risk is necessary in the current investing environment.
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q1 2022 Results - Earnings Call Transcript 2022/05/13 00:52:04 Seeking Alpha
Regulus Therapeutics, Inc. (NASDAQ:NASDAQ:RGLS) Q1 2022 Earnings Conference Call May 12, 2022, 17:00 ET Company Participants Crispina Calsada - CFO Joseph Hagan - President, CEO &…
Regulus Therapeutics GAAP EPS of -$0.05 2022/05/12 20:09:04 Seeking Alpha
Regulus Therapeutics press release (RGLS): Q1 GAAP EPS of -$0.05.Research and development expenses were $3.7M.
Hottest Stock Now: MICT, Inc. (NASDAQ:MICT), Regulus Therapeutics Inc. (NASDAQ:RGLS) 2022/04/07 01:55:16 Stock Equity
MICT, Inc. (MICT) with the stream of 0.87% also noticed, India Regulus Therapeutics Inc. (RGLS) encountered a rapid change of 0.98% in the last hour of Wednesday’s trading session. MICT, … The post Hottest Stock Now: MICT, Inc. (NASDAQ:MICT), Regulus Therapeutics Inc. (NASDAQ:RGLS) appeared first on Stocks Equity .
Regulus Therapeutics Inc. (NASDAQ: RGLS) Is Up 3.21% Year-To-Date, But Analysts Find Room For A Price Rally 2022/04/04 15:30:00 Stocks Register
Regulus Therapeutics Inc. (NASDAQ:RGLS) traded at $0.33 at close of the session on Friday, 04/01/22, made an upward move of 9.09% on its previous day’s price. Looking at the stock we see that its previous close was $0.30 and the beta (5Y monthly) reads 2.01 with the day’s price range being $0.295 – $0.3295. In … Regulus Therapeutics Inc. (NASDAQ: RGLS) Is Up 3.21% Year-To-Date, But Analysts Find Room For A Price Rally Read More »
Regulus Therapeutics Inc. (NASDAQ: RGLS) Is Down -2.30% In A Month. Could There Be Any Hope That It Will Rise Soon? 2022/04/01 14:30:00 Marketing Sentinel
During the last session, Regulus Therapeutics Inc. (NASDAQ:RGLS)’s traded shares were 1.1 million, with the beta value of the company hitting 2.13. At the end of the trading day, the stock’s price was $0.30, reflecting an intraday gain of 2.69% or $0.01. The 52-week high for the RGLS share is $1.63, that puts it down … Regulus Therapeutics Inc. (NASDAQ: RGLS) Is Down -2.30% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »
Regulus Starts Preclinical Studies In ALS Under Pact With Brigham and Women''s Hospital 2022/03/24 16:03:00 Benzinga
Regulus Therapeutics Inc (NASDAQ: RGLS ) has initiated studies to evaluate a library of oligonucleotides to block miR-155 for Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig''s disease) under a collaboration agreement with Harvard''s Brigham and Women''s Hospital (BWH). The agreement, effective since September … Full story available on Benzinga.com
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi 2022/03/18 12:48:16 Benzinga
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney disease called Alport syndrome may be in for some life-altering news in the year ahead. Last month, Regulus Therapeutics (Nasdaq: RGLS ) announced completion of enrollment in the Phase 2 HERA study of lademirsen, a drug candidate for the treatment of Alport syndrome licensed exclusively to Sanofi (Nasdaq: SNY ). Under the terms of the agreement, Sanofi is responsible for all remaining development and commercialization costs and Regulus is eligible for $25 million in remaining milestone payments. The degenerative kidney disease is estimated to afflict 30,000 to 60,000 patients in the US alone. In 2020 Regulus achieved $10 million in milestone payments from Sanofi associated with the completion of transfer and verification of certain materials as well as an interim enrollment milestone for progress with the HERA study.